These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 8069557

  • 1. Review: recent advances in lipid microsphere technology for targeting prostaglandin delivery.
    Mizushima Y, Hoshi K.
    J Drug Target; 1993; 1(2):93-100. PubMed ID: 8069557
    [Abstract] [Full Text] [Related]

  • 2. Prostaglandin E1 incorporated in lipid microspheres (lipo PGE1).
    Otomo S, Mizushima Y, Aihara H, Yokoyama K, Watanabe M, Yanagawa A.
    Drugs Exp Clin Res; 1985; 11(9):627-31. PubMed ID: 3880049
    [Abstract] [Full Text] [Related]

  • 3. Prostaglandin E1 incorporated in lipid microspheres in the treatment of peripheral vascular diseases and diabetic neuropathy.
    Hoshi K, Mizushima Y, Kiyokawa S, Yanagawa A.
    Drugs Exp Clin Res; 1986; 12(8):681-5. PubMed ID: 3757764
    [Abstract] [Full Text] [Related]

  • 4. A multicenter double blind controlled study of lipo-PGE1, PGE1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders.
    Mizushima Y, Shiokawa Y, Homma M, Kashiwazaki S, Ichikawa Y, Hashimoto H, Sakuma A.
    J Rheumatol; 1987 Feb; 14(1):97-101. PubMed ID: 3553591
    [Abstract] [Full Text] [Related]

  • 5. A comparison of the effect of Lipo PGE1 and other related compounds on experimental peripheral arterial occlusive disease in rats.
    Goto J, Araki H, Otomo S, Aihara H.
    Drugs Exp Clin Res; 1986 Feb; 12(11):917-21. PubMed ID: 3816509
    [Abstract] [Full Text] [Related]

  • 6. Lipid microspheres for drug delivery from the pharmaceutical viewpoint.
    Yamaguchi T, Mizushima Y.
    Crit Rev Ther Drug Carrier Syst; 1994 Feb; 11(4):215-29. PubMed ID: 7664347
    [Abstract] [Full Text] [Related]

  • 7. Treatment of established collagen induced arthritis with prostaglandin E1 incorporated in lipid microspheres.
    Moriuchi-Murakami E, Yamada H, Ishii O, Kikukawa T, Igarashi R.
    J Rheumatol; 2000 Oct; 27(10):2389-96. PubMed ID: 11036835
    [Abstract] [Full Text] [Related]

  • 8. Inhibitory effects of alprostadil (prostaglandin E1) incorporated in lipid microspheres of soybean oil on intimal hyperplasia following balloon injury in rabbits.
    Kunihara M, Tsuchida K, Kaneko K, Suga H, Hasegawa T, Mochizuki S, Kawai K, Shiga A, Yamaguchi T.
    Arzneimittelforschung; 2002 Oct; 52(5):358-64. PubMed ID: 12087920
    [Abstract] [Full Text] [Related]

  • 9. Prostaglandin E1 in lipid microspheres ameliorates diabetic peripheral neuropathy: clinical usefulness of Semmes-Weinstein monofilaments for evaluating diabetic sensory abnormality.
    Akahori H, Takamura T, Hayakawa T, Ando H, Yamashita H, Kobayashi K.
    Diabetes Res Clin Pract; 2004 Jun; 64(3):153-9. PubMed ID: 15126001
    [Abstract] [Full Text] [Related]

  • 10. Marked hypotensive and blood flow-increasing effects of a new lipo-PGE(1) (lipo-AS013) due to vascular wall targeting.
    Igarashi R, Takenaga M, Takeuchi J, Kitagawa A, Matsumoto K, Mizushima Y.
    J Control Release; 2001 Apr 02; 71(2):157-64. PubMed ID: 11274747
    [Abstract] [Full Text] [Related]

  • 11. Lipo-PGE1, a new lipid-encapsulated preparation of prostaglandin E1: placebo-and prostaglandin E1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers.
    Toyota T, Hirata Y, Ikeda Y, Matsuoka K, Sakuma A, Mizushima Y.
    Prostaglandins; 1993 Nov 02; 46(5):453-68. PubMed ID: 8278621
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The effect of prostaglandin E1 incorporated in lipid microspheres on thrombus formation and thrombus disaggregation and its potential to target to the site of vascular lesions.
    Sim AK, McCraw AP, Cleland ME, Aihara H, Otomo S, Hosoda K.
    Arzneimittelforschung; 1986 Aug 02; 36(8):1206-9. PubMed ID: 3778557
    [Abstract] [Full Text] [Related]

  • 14. Interaction between non-ionic contrast medium and prostaglandin E1 incorporated in lipid microspheres: in-vitro comparative study of direct and non-direct mixing.
    Hayashi H, Uchiyama N, Kawamata H, Takagi R, Abe Y, Kumazaki T.
    Radiat Med; 2000 Aug 02; 18(4):219-25. PubMed ID: 11246996
    [Abstract] [Full Text] [Related]

  • 15. Lipid microspheres as novel drug carriers.
    Mizushima Y.
    Drugs Exp Clin Res; 1985 Aug 02; 11(9):595-600. PubMed ID: 3880046
    [Abstract] [Full Text] [Related]

  • 16. Uptake by vascular smooth muscle cells plays an important role in targeting of lipid microspheres incorporating prostaglandin E1 into a thickened intima.
    Chino Y, Minagawa T, Kohno Y, Toda Y, Murakami S, Higuchi S.
    Life Sci; 2001 Jan 12; 68(8):933-42. PubMed ID: 11213363
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Development of new drugs for intractable vasculitis--lipo-PGE1 and monoclonal antibody].
    Matsuda T, Hoshi K, Igarashi R, Ichikawa Y.
    Nihon Rinsho; 1994 Aug 12; 52(8):2187-91. PubMed ID: 7933610
    [Abstract] [Full Text] [Related]

  • 19. Distribution of lipid microspheres incorporating prostaglandin E1 to vascular lesions.
    Mizushima Y, Hamano T, Haramoto S, Kiyokawa S, Yanagawa A, Nakura K, Shintome M, Watanabe M.
    Prostaglandins Leukot Essent Fatty Acids; 1990 Dec 12; 41(4):269-72. PubMed ID: 2077541
    [Abstract] [Full Text] [Related]

  • 20. Vasodilating effect and tissue accumulation of prostaglandin E1 incorporated in lipid microspheres on the rat ductus arteriosus.
    Chino Y, Minagawa T, Kohno Y, Fukushima K, Momma K.
    Jpn J Pharmacol; 1999 Sep 12; 81(1):107-14. PubMed ID: 10580378
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.